Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment
Dow Jones
Jul 11
Q32 Bio's stock surged after the company disclosed plans to report on the results of a drug trial evaluating an immunotherapy's effects on alopecia areta on Monday.
Shares were up 38% to $15.47 in after-hours trading on Friday. Through the market's close the stock has risen more than three fold this year.
The clinical stage biotechnology will release the results 8:00 a.m. ET.
The trial evaluated how bempikibart affected patients with severe or very severe alopecia areta, an autoimmune disorder that causes hair loss.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
July 10, 2026 17:37 ET (21:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.